Kayshild
What Kayshild is used for
Kayshild is indicated in conjunction with diet and exercise for the treatment of adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis (fibrosis stages F2 to F3).
Approved use, as published by the European Medicines Agency.
What the labels mean
- Conditional approval: approved on less complete data because the need is high; more data must follow.
Key facts
- Brand
- Kayshild
- Active substance
- semaglutide
- Disease area
- Non-alcoholic Fatty Liver Disease; Liver Cirrhosis
- Medicine group
- Drugs used in diabetes
- ATC code
- A10BJ06
- Marketing authorisation holder
- Novo Nordisk A/S
- Authorised in the EU since
- 2026
Official information
In India
- Semaglutide: 3 brands in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Kayshild used for?
Kayshild is indicated in conjunction with diet and exercise for the treatment of adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis (fibrosis stages F2 to F3).
What is the active substance in Kayshild?
Kayshild contains semaglutide.
Who makes Kayshild?
The EU marketing authorisation holder is Novo Nordisk A/S.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU